Celixir Ltd:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Celixir Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11228
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:20
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Celixir Ltd (CTL), formerly Cell Therapy Ltd is a biotechnology company that discovers and develops regenerative medicines using adult stem cells for the treatment of heart failure. The company provids heartcel which is a type of stem cell therapy that provides improved outcomes for end-stage heart failure patients. Its iMP regenerative cells are mesodermal progenitor cells that act as potent cardio-specific cellular therapy for cardiac regeneration. Celixir’s platelet therapies enhance tissue regeneration and wound healing through secretion of platelet-derived growth factor, transforming growth factor and epithelial growth factor, among others. The company’s PML cells are under clinical research to be investigated as a treatment for patients with mild to moderate heart failure. It collaborates with biotech companies to develop new products. Celixir is headquartered in Stratford-upon-Avon, the UK.

Celixir Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Celixir Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Celixir Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Celixir Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Celixir Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Celixir Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Celixir Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Celixir Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Celixir Raises USD1.5 Million in Venture Financing 11
Celixir (Cell Therapy) Secures USD1.08 Million in Venture Funding 12
Partnerships 13
Zhongyuan Union Stem Cell Forms Joint Venture With Cell Therapy For Stem Cell Research 13
Licensing Agreements 14
Daiichi Sankyo Enters into Licensing Agreement with Cell Therapy 14
Celixir Ltd – Key Competitors 15
Celixir Ltd – Key Employees 16
Celixir Ltd – Locations And Subsidiaries 17
Head Office 17
Recent Developments 18
Corporate Communications 18
Feb 26, 2018: Celixir appoints Dr Mubasher Sheikh as Chairman of the Board 18
Other Significant Developments 19
Feb 14, 2018: The Alliance for Regenerative Medicine Announces Initial Slate of Presenting Companies at the Sixth Annual Cell & Gene Therapy Investor Day 19
Appendix 20
Methodology 20
About GlobalData 20
Contact Us 20
Disclaimer 20

List of Tables
Celixir Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Celixir Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Celixir Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Celixir Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Celixir Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Celixir Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Celixir Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Celixir Raises USD1.5 Million in Venture Financing 11
Celixir (Cell Therapy) Secures USD1.08 Million in Venture Funding 12
Zhongyuan Union Stem Cell Forms Joint Venture With Cell Therapy For Stem Cell Research 13
Daiichi Sankyo Enters into Licensing Agreement with Cell Therapy 14
Celixir Ltd, Key Competitors 15
Celixir Ltd, Key Employees 16

List of Figures
Celixir Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Celixir Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Celixir Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Celixir Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Celixir Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Celixir Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Celixir Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Celixir Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Celixir Ltd, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Celixir Ltd:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • GE Global Research-医療機器分野:企業M&A・提携分析
    Summary GE Global Research (GE Global), a subsidiary of General Electric Company is a research and development company that develops technologies for various industry sectors. The company offers diverse technologies which are used in electronics, chemistry, biosciences, computing, metallurgy, fluid …
  • PrairieSky Royalty Ltd (PSK):石油・ガス:M&Aディール及び事業提携情報
    Summary PrairieSky Royalty Ltd (PrairieSky Royalty) is an oil and gas company. The company carries out acquisition of fee simple lands from Encana Corporation and concurrent initial public offering. It also acquires and manages royalty lands, to generate free cash flow through indirect third-party o …
  • ZIOPHARM Oncology Inc (ZIOP):企業の財務・戦略的SWOT分析
    Summary Ziopharm Oncology Inc (Ziopharm), is a provider of next-generation immune therapies. The company offers Controlled IL-12 and t-cell therapy to fight blood cancers and solid tumors. Its Controlled IL-12 platform provides therapy for cold tumors by turning them hot by activating an immune resp …
  • Dorel Industries Inc.:企業の戦略・SWOT・財務情報
    Dorel Industries Inc. - Strategy, SWOT and Corporate Finance Report Summary Dorel Industries Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Yantai Dongcheng Pharmaceutical Group Co Ltd (002675):製薬・医療:M&Aディール及び事業提携情報
    Summary Yantai Dongcheng Pharmaceutical Group Co Ltd (Yantai Dongcheng Pharma), formerly Yantai Dongcheng Biochemicals Co Ltd, is a developer, manufacturer, and marketer of biochemical API, chemical synthetic drugs, and Chinese medicines. The company offers its products under categories including he …
  • Suncor Energy Inc Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    Suncor Energy Inc Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary Suncor Energy Inc. (Suncor) is an integrated energy company that mainly focuses on the development of Athabasca oil sands. It carries out development and up gradation of oil sands; offshore and ons …
  • Expeditors International of Washington, Inc.:企業の戦略・SWOT・財務情報
    Expeditors International of Washington, Inc. - Strategy, SWOT and Corporate Finance Report Summary Expeditors International of Washington, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operati …
  • Bracco Imaging SpA-医療機器分野:企業M&A・提携分析
    Summary Bracco Imaging SpA (Bracco), a subsidiary of Bracco SpA is a provider of diagnostic imaging solutions. The company offers diagnostic imaging, bracco pharma and health services. It offers solutions which include X-Ray, CT colonography, magnetic resonance imaging, diagnostic radiology, endosco …
  • Elos Medtech AB (ELOS B):企業の財務・戦略的SWOT分析
    Elos Medtech AB (ELOS B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Graftys SA-医療機器分野:企業M&A・提携分析
    Summary Graftys SA (Graftys) is a medical device company that focuses on the development, manufacture and commercialization of synthetic bioactive orthopedic biomaterials. It provides a wide range of synthetic and bioresorbable bone graft substitutes and other cement products. The company’s products …
  • Mithra Pharmaceuticals SA (MITRA):製薬・医療:M&Aディール及び事業提携情報
    Summary Mithra Pharmaceuticals SA (Mithra) is a developer and manufacturer of over the counter products and prescription drugs for women’s health and other applications. The company offers products such as estelle, donesta, tibelia, zoreline and myring, among others. Its products are used in the tre …
  • Schindler Holding Ltd.:企業の戦略・SWOT・財務情報
    Schindler Holding Ltd. - Strategy, SWOT and Corporate Finance Report Summary Schindler Holding Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Crown Bioscience Inc (6554):製薬・医療:M&Aディール及び事業提携情報
    Summary Crown Bioscience Inc (Crown Bioscience) is a drug discovery company that provides drug discovery and development services. The company offers antibodies, proteins, cell lines, tumor samples, in vivo and in vitro research reagents. It offers services such as preclinical research services, onc …
  • Tractebel Engineering S.A.:企業の戦略的SWOT分析
    Tractebel Engineering S.A. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Carmell Therapeutics Corp:医療機器:M&Aディール及び事業提携情報
    Summary Carmell Therapeutics Corp (Carmell) is a biotechnology company that develops and commercializes bone healing accelerants and tissue healing accelerants. Its pipeline portfolio include adjunctive treatment for long bone fractures in Phase I and Phase II a; and adjunctive treatment for total j …
  • Valensa International LLC:企業の戦略・SWOT・財務分析
    Valensa International LLC - Strategy, SWOT and Corporate Finance Report Summary Valensa International LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Northbridge Financial Corporation:企業の戦略的SWOT分析
    Northbridge Financial Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • Maruho Co Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Maruho Co Ltd (Maruho) is a pharmaceutical company that carries out the research, development, production, and distribution of dermatological products. It product portfolio includes a wide range of prescription drugs, medical devices and other skincare products. The company also offers produ …
  • MRF Limited:企業の戦略・SWOT・財務情報
    MRF Limited - Strategy, SWOT and Corporate Finance Report Summary MRF Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Thin Film Electronics ASA (THIN):企業の財務・戦略的SWOT分析
    Thin Film Electronics ASA (THIN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆